Gillian D. Sanders, PhD; Mark A. Hlatky, MD; Nathan R. Every, MD, MPH; Kathryn M. McDonald, MM; Paul A. Heidenreich, MD, MS; Lori S. Parsons, BS; Douglas K. Owens, MD, MS
Acknowledgments: The authors thank the other investigators in the Cardiac Arrhythmia and Risk of Death Patient Outcomes Research Team (CARD PORT) for reviewing the model and data sources. They also thank Lyn Dupré for editorial assistance.
Grant Support: In part by the Cardiac Arrhythmia and Risk of Death Patient Outcomes Research Team grant (HS 08362) to Stanford University from the Agency for Health Care Policy and Research. Drs. Owens, Heidenreich, and Every are supported by Career Development Awards from the Veterans Affairs Health Services Research and Development Service.
Requests for Single Reprints: Gillian D. Sanders, PhD, Center for Primary Care and Outcomes Research, 179 Encina Commons, Stanford University, Stanford, CA 94305-6019; e-mail, email@example.com.
Current Author Addresses: Drs. Sanders and Owens and Ms. McDonald: Center for Primary Care and Outcomes Research, 179 Encina Commons, Stanford University, Stanford, CA 94305-6019.
Drs. Hlatky and Heidenreich: Department of Health Research and Policy, HRP Building, Stanford University, Stanford, CA 94305-5405.
Dr. Every: Frazier & Co., 601 Union Street, Suite 3300, Seattle, WA 98101.
Ms. Parsons: Ovation Research Group, 805 Fir Place, Edmunds, WA 98020.
Author Contributions: Conception and design: G.D. Sanders, M.A. Hlatky, N.R. Every, K.M. McDonald, P.A. Heidenreich, D.K. Owens.
Analysis and interpretation of the data: G.D. Sanders, M.A. Hlatky, N.R. Every, K.M. McDonald, P.A. Heidenreich, L.S. Parsons, D.K. Owens.
Drafting of the article: G.D. Sanders, M.A. Hlatky, K.M. McDonald, D.K. Owens.
Critical revision of the article for important intellectual content: G.D. Sanders, M.A. Hlatky, N.R. Every, K.M. McDonald, P.A. Heidenreich, D.K. Owens.
Final approval of the article: G.D. Sanders, M.A. Hlatky, N.R. Every, K.M. McDonald, P.A. Heidenreich, L.S. Parsons, D.K. Owens.
Provision of study materials or patients: M.A. Hlatky, N.R. Every.
Statistical expertise: G.D. Sanders, M.A. Hlatky, N.R. Every, L.S. Parsons, D.K. Owens.
Obtaining of funding: M.A. Hlatky, N.R. Every, K.M. McDonald, D.K. Owens.
Administrative, technical, or logistic support: K.M. McDonald.
Collection and assembly of data: G.D. Sanders, M.A. Hlatky, K.M. McDonald, L.S. Parsons.
Clinical trials have shown that implantable cardioverter defibrillators (ICDs) improve survival in patients with sustained ventricular arrhythmias.
To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction.
Markov model–based cost utility analysis.
Survival, cardiac death, and inpatient costs were estimated on the basis of the Myocardial Infarction Triage and Intervention registry. Other data were derived from the literature.
Patients with past myocardial infarction who did not have sustained ventricular arrhythmia.
ICD or amiodarone compared with no treatment.
Life-years, quality-adjusted life-years (QALYs), costs, number needed to treat, and incremental cost-effectiveness.
Compared with no treatment, ICD use led to the greatest QALYs and the highest expenditures. Amiodarone use resulted in intermediate QALYs and costs. To obtain acceptable cost-effectiveness thresholds (≤$75 000/QALY), ICDs had to reduce arrhythmic death by 50% and amiodarone had to reduce total death by 7% in patients with depressed ejection fraction.
For moderate efficacies, in patients with ejection fractions less than or equal to 0.3, 0.31 to 0.4, and greater than 0.4, the cost-effectiveness of amiodarone compared with no therapy was $43 100/QALY, $66 500/QALY, and $132 500/QALY, respectively, and the cost-effectiveness of ICD compared with amiodarone was $71 800/QALY, $195 700/QALY, and $557 900/QALY, respectively.
Use of ICD or amiodarone in patients with past myocardial infarction and severely depressed left ventricular function may provide substantial clinical benefit at an acceptable cost. These results highlight the importance of clinical trials of ICDs in patients with low ejection fractions who have had myocardial infarction.
Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction. Ann Intern Med. ;135:870–883. doi: 10.7326/0003-4819-135-10-200111200-00007
Download citation file:
Published: Ann Intern Med. 2001;135(10):870-883.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use